Artivion Inc, formerly CryoLife Inc, is a medical device company. It specializes in the manufacturing, processing, and distribution of medical devices and implantable human tissues. The company's product portfolio includes aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion's products are primarily used in cardiac and vascular surgeries, catering to patients with aortic conditions. The company markets its products and preservation services directly to physicians in the US and Canada and utilizes independent distributors and subsidiaries in the EMEA, APAC, and LATAM regions. Artivion operates globally, with manufacturing centers in Kennesaw, Georgia; Austin, Texas and Hechingen, Germany. Artivion Inc is headquartered in Kennesaw, Georgia, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company Artivion Inc
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Artivion Inc Company Overview
Artivion Inc Company Snapshot
Artivion Inc Pipeline Products and Ongoing Clinical Trials Overview
Artivion Inc – Pipeline Analysis Overview
Business Description
Artivion Inc - Key Facts
Artivion Inc - Major Products and Services
Artivion Inc Pipeline Products by Development Stage
Artivion Inc Ongoing Clinical Trials by Trial Status
Apr 29, 2024: Artivion Announces Presentation of New Clinical Data for On-X Aortic Heart Valve and AMDS at the 104th American Association for Thoracic Surgery (AATS) Annual Meeting
Jan 29, 2024: Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE Trial at the 60th Society of Thoracic Surgery Annual Meeting
Nov 09, 2023: Artivion Announces Completion of Enrollment in PERSEVERE Trial
Oct 19, 2023: Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2023 Financial Results
Oct 05, 2023: Artivion Announces Presentation of Late-Breaking Interim Data from AMDS PERSEVERE Trial at the 37th European Association for Cardio-Thoracic Surgery Annual Meeting
May 30, 2023: ‘Korea Needs to Localize Rare Medical Devices Amid Global Supply Shortage’
May 24, 2023: Artivion secures FDA PMA approval for PerClot
E-liac Stent Graft System - Prospective Multicenter Registry to Examine the Real-world Performance of the E-liac Stent Graft System for Treatment of Uni- or Bilateral Aorto-iliac or Iliac Aneurysms
E-Ventus SX - Product Status
E-Ventus SX - Product Description
E-Vita Open Neo - Product Status
E-Vita Open Neo - Product Description
E-Vita Open Neo - A Post-market Clinical Follow-up Study in Patients with Acute or Chronic Aortic Dissection or Aortic Aneurysm Treated with E-vita OPEN NEO: NEOS
E-Vita Open Neo - NEO - E-vita Open Neo Treatment of Aortic Arch Aneurysms and Dissections
E-Vita Open Neo - NEOS-APAC - Asian Pacific Post-market Clinical Follow-up Study in Patients with Acute or Chronic Aortic Dissection or Aortic Aneurysm Treated with E-vita OPEN NEO
Neo 2.0 - Product Status
Neo 2.0 - Product Description
On-X Mechanical Aortic Valve - ELIQUIS - Product Status